Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets
JournalClinical and Translational Science
PublisherBlackwell Publishing Ltd
MetadataShow full item record
AbstractThere have been literature reports that some recommended meropenem dosage regimens may fail to meet therapeutic targets in some high‐risk children and adults. We evaluated this observation in children using literature studies conducted in infants and children. Observed and, as necessary, simulated data from the literature were combined, yielding a data set of 288 subjects (1 day to ~ 17 years). A population pharmacokinetic model was fit to the data and then used to simulate the recommended dosing regimens and estimate the proportion of subjects achieving recommended target exposures. A two‐compartment model best fit the data with weight, postnatal age, gestational age, and serum creatinine as covariates. The US Food and Drug Administration (FDA)‐approved dosing regimens achieved targets in ~ 90% or more of subjects > 3 months of age for organisms with minimum inhibitory concentration (MIC)'s of 2 and 4 mg/L; however, only 68.4% and 41.7% of subjects older than 3 months and weighing < 50 kg achieved target exposures for organisms with MIC's of 2 and 4 mg/L, respectively. Moreover, for subjects weighing more than 50 kg, only 41.3% and 17% achieved these respective targets. Simulation studies were used to explore the impact of changing dose, dosing interval, and infusion duration on the likelihood of achieving therapeutic targets in these groups. Our findings illustrate that current dosing recommendations for children over 3 months of age fail to meet therapeutic targets in an unacceptable fraction of patients. Further investigation is needed to develop new dosing strategies in these patients. Copyright 2019 The Authors.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075249846&doi=10.1111%2fcts.12710&partnerID=40&md5=cfb144c0768429c49f8a708b26022083; http://hdl.handle.net/10713/11480
- Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
- Authors: Kongthavonsakul K, Lucksiri A, Eakanunkul S, Roongjang S, Issaranggoon Na Ayuthaya S, Oberdorfer P
- Issue date: 2016 Aug
- Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
- Authors: Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP
- Issue date: 2006 Nov
- Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
- Authors: Ohata Y, Tomita Y, Sunakawa K, Drusano GL, Tanigawara Y
- Issue date: 2019 Sep
- Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
- Authors: Ellis JM, Kuti JL, Nicolau DP
- Issue date: 2005 Nov
- Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
- Authors: Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV
- Issue date: 2016 Apr